Skip to main content
Log in

US FDA issues summary of recent updates for ARBs

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. ARB = angiotensin type 2 receptor blocker

  2. including the gas chromatography-mass spectrometry [GC/MS] headspace method; the combined headspace method; and the combined direct injection method

  3. NDMA = N-nitrosodimethylamine; NDEA = N-nitrosodiethylamine

  4. including amlodipine/valsartan tablets, valsartan tablets andvalsartan/hydrochlorothiazide tablets

  5. including all lots of amlodipine/valsartan tablets and amlodipine/valsartan/hydrochlorothiazide tablets

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

US FDA issues summary of recent updates for ARBs. Reactions Weekly 1733, 4 (2018). https://doi.org/10.1007/s40278-018-55803-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-55803-7

Navigation